← Leaderboards
Robert Swift
Invenux, Llc
$2,789,416
Attributed
$2,789,416
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2013–17$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$2,789,416 · 5
By mechanism
R44$1,499,750 · 1
R43$891,740 · 3
R41$397,926 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Affect”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$287,585,588
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$209,385,844
- David Heimbrook · Leidos Biomedical Research, Inc.$168,138,264
- Daniel R Kuritzkes · Brigham And Women'S Hospital$151,687,019
Research focus
AffectGrantPharmaceutical PreparationsUnited StatesIn VivoIn VitroHydroxyureaPainSickle CellStrokeCessation Of LifeErythrocytesAntineoplastic AgentsAdultChildBotanicalsMedicalCostDeveloping CountriesQuality Of LifeSickle Cell AnemiaInheritedDisease ProgressionHemoglobin
Grant awards (6)
Safety Studies for Clinical Trials of a Botanical Drug for Sickle Cell Disease$692,340
R44 · FY2017 · HL · contact PI
Crossover Study of an Oral Treatment for Sickle Cell Disease$224,950
R43 · FY2017 · HL · contact PI
Identification of the Antisickling Compounds in SCD-101$224,731
R43 · FY2017 · HL · contact PI
Safety Studies for Clinical Trials of a Botanical Drug for Sickle Cell Disease$807,410
R44 · FY2016 · HL · contact PI
First Clinical Trial of an Anti-Sickling Botanical Drug for Sickle Cell Dise$442,059
R43 · FY2013 · HL · contact PI
Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity$397,926
R41 · FY2013 · AT · contact PI